(UroToday.com) In a plenary session at the Society of Urologic Oncology Annual Meeting focused on early prostate cancer diagnosis and treatment, Dr. Burcu Darst discussed the role of polygenic risk scores (PRS) to improve prostate-specific antigen (PSA)-based prostate cancer screening.